Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Triple-negative breast cancer: promising prognostic biomarkers currently in development76
TIM-3 pathway dysregulation and targeting in cancer52
Molecular therapeutic targets in non-small cell lung cancer43
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis37
The potential of PSMA-targeted alpha therapy in the management of prostate cancer30
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy30
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies28
TKIs in combination with immunotherapy for hepatocellular carcinoma27
The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review26
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer26
Asbestos-related cancers: the ‘Hidden Killer’ remains a global threat25
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy25
Current radiotherapy techniques in NSCLC: challenges and potential solutions24
Treatment of recurrent glioblastoma: state-of-the-art and future perspectives23
Optimal treatment in locally advanced cervical cancer22
The emerging role of antibody-drug conjugates in urothelial carcinoma21
Pediatric relapsed acute myeloid leukemia: a systematic review21
The role of the microbiome in drug resistance in gastrointestinal cancers21
New insights into ErbB3 function and therapeutic targeting in cancer20
What is the best clinical approach to recurrent/refractory osteosarcoma?20
How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer20
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies20
0.034686088562012